Oseltamivir-zanamivir combination therapy suppresses drug-resistant H1N1 influenza A viruses in the hollow fiber infection model (HFIM) system

European Journal of Pharmaceutical Sciences

Volumn 111, Issue , 2018, Pages 443-449

  Pires de Mello, Camilly P ^a   Drusano, George L ^a   Adams, Jonathan R ^a,b   Shudt, Matthew ^b   Kulawy, Robert ^a   Brown, Ashley N ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b WADSWORTH CENTER   (United States)

Author keywords

Combination therapy; Hollow fiber infection model system; Pharmacodynamics; Pharmacokinetics

Indexed keywords

4 ACETAMIDO 5 AMINO 3 (1 ETHYLPROPOXY) 1 CYCLOHEXENE 1 CARBOXYLIC ACID; SIALIDASE; ZANAMIVIR; ANTIVIRUS AGENT; OSELTAMIVIR;

ANTIVIRAL ACTIVITY; ARTICLE; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; CROSS RESISTANCE; DRUG BINDING; ENZYME ACTIVE SITE; INFLUENZA A VIRUS (H1N1); NONHUMAN; PRIORITY JOURNAL; VIRUS REPLICATION; VIRUS STRAIN; ANIMAL; CELL LINE; COMBINATION DRUG THERAPY; DOG; DRUG EFFECT; HUMAN; VIRUS CULTURE;

ANIMALS; ANTIVIRAL AGENTS; CELL LINE; DOGS; DRUG THERAPY, COMBINATION; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; OSELTAMIVIR; VIRUS CULTIVATION; ZANAMIVIR;

EID: 85032282560     PISSN: 09280987     EISSN: 18790720     Source Type: Journal    
DOI: 10.1016/j.ejps.2017.10.027     Document Type: Article

References (40)

1. Autran, B., Carcelain, G., Li, T.S., Blanc, C., Mathez, D., Tubiana, R., Katlama, C., Debre, P., Leibowitch, J., Positive effects of combined antiretroviral therapy on CD4 + T cell homeostasis and function in advanced HIV disease. Science 277 (1997), 112–116.
2. Brown, A.N., McSharry, J.J., Weng, Q., Driebe, E.M., Engelthaler, D.M., Sheff, K., Keim, P.S., Nguyen, J., Drusano, G.L., In vitro system for modeling influenza A virus resistance under drug pressure. Antimicrob. Agents Chemother. 54 (2010), 3442–3450.
3. Brown, A.N., Bulitta, J.B., McSharry, J.J., Weng, Q., Adams, J.R., Kulawy, R., Drusano, G.L., Effect of half-life on the pharmacodynamic index of zanamivir against influenza virus delineated by a mathematical model. Antimicrob. Agents Chemother. 55 (2011), 1747–1753.
4. Brown, A.N., McSharry, J.J., Weng, Q., Adams, J.R., Kulawy, R., Drusano, G.L., Zanamivir, at 600 milligrams twice daily, inhibits oseltamivir-resistant 2009 pandemic H1N1 influenza virus in an in vitro hollow-fiber infection model system. Antimicrob. Agents Chemother. 55 (2011), 1740–1746.
5. Carrat, F., Duval, X., Tubach, F., Mosnier, A., van der Werf, S., Tibi, A., Blanchon, T., Leport, C., Flahault, A., Mentre, F., Effect of oseltamivir, zanamivir or oseltamivir-zanamivir combination treatments on transmission of influenza in households. Antivir. Ther. 17 (2012), 1085–1090.
6. CDC, 2008–2009 Influenza Season Week 38 Ending September 26, 2009. 2009, Centers for Disease Control and Prevention.
7. CDC, Oseltamivir-resistant 2009 pandemic influenza A (H1N1) virus infection in two summer campers receiving prophylaxis—North Carolina, 2009. MMWR Morb. Mortal. Wkly Rep. 58 (2009), 969–972.
8. CDC, Oseltamivir-resistant novel influenza A (H1N1) virus infection in two immunosuppressed patients—Seattle, Washington, 2009. MMWR Morb. Mortal. Wkly Rep. 58 (2009), 893–896.
9. CDC, Use of influenza A (H1N1) 2009 monovalent vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. MMWR Recomm. Rep. 58 (2009), 1–8.
10. de Jong, M.D., Tran, T.T., Truong, H.K., Vo, M.H., Smith, G.J., Nguyen, V.C., Bach, V.C., Phan, T.Q., Do, Q.H., Guan, Y., Peiris, J.S., Tran, T.H., Farrar, J., Oseltamivir resistance during treatment of influenza A (H5N1) infection. N. Engl. J. Med. 353 (2005), 2667–2672.
11. Deyde, V.M., Sheu, T.G., Trujillo, A.A., Okomo-Adhiambo, M., Garten, R., Klimov, A.I., Gubareva, L.V., Detection of molecular markers of drug resistance in 2009 pandemic influenza A (H1N1) viruses by pyrosequencing. Antimicrob. Agents Chemother. 54 (2010), 1102–1110.
12. Diggory, P., Fernandez, C., Humphrey, A., Jones, V., Murphy, M., Comparison of elderly people's technique in using two dry powder inhalers to deliver zanamivir: randomised controlled trial. BMJ 322 (2001), 577–579.
13. Doucette, K.E., Aoki, F.Y., Oseltamivir: a clinical and pharmacological perspective. Expert. Opin. Pharmacother. 2 (2001), 1671–1683.
14. Dulek, D.E., Williams, J.V., Creech, C.B., Schulert, A.K., Frangoul, H.A., Domm, J., Denison, M.R., Chappell, J.D., Use of intravenous zanamivir after development of oseltamivir resistance in a critically ill immunosuppressed child infected with 2009 pandemic influenza A (H1N1) virus. Clin. Infect. Dis. 50 (2010), 1493–1496.
15. Duval, X., van der Werf, S., Blanchon, T., Mosnier, A., Bouscambert-Duchamp, M., Tibi, A., Enouf, V., Charlois-Ou, C., Vincent, C., Andreoletti, L., Tubach, F., Lina, B., Mentre, F., Leport, C., Efficacy of oseltamivir-zanamivir combination compared to each monotherapy for seasonal influenza: a randomized placebo-controlled trial. PLoS Med., 7, 2010, e1000362.
16. Escuret, V., Cornu, C., Boutitie, F., Enouf, V., Mosnier, A., Bouscambert-Duchamp, M., Gaillard, S., Duval, X., Blanchon, T., Leport, C., Gueyffier, F., van der Werf, S., Lina, B., Oseltamivir-zanamivir bitherapy compared to oseltamivir monotherapy in the treatment of pandemic 2009 influenza A(H1N1) virus infections. Antivir. Res. 96 (2012), 130–137.
17. Foster, G.R., Afdhal, N., Roberts, S.K., Brau, N., Gane, E.J., Pianko, S., Lawitz, E., Thompson, A., Shiffman, M.L., Cooper, C., Towner, W.J., Conway, B., Ruane, P., Bourliere, M., Asselah, T., Berg, T., Zeuzem, S., Rosenberg, W., Agarwal, K., Stedman, C.A., Mo, H., Dvory-Sobol, H., Han, L., Wang, J., McNally, J., Osinusi, A., Brainard, D.M., McHutchison, J.G., Mazzotta, F., Tran, T.T., Gordon, S.C., Patel, K., Reau, N., Mangia, A., Sulkowski, M., Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection. N. Engl. J. Med. 373 (2015), 2608–2617.
18. Gane, E.J., Stedman, C.A., Hyland, R.H., Ding, X., Svarovskaia, E., Symonds, W.T., Hindes, R.G., Berrey, M.M., Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N. Engl. J. Med. 368 (2013), 34–44.
19. Ghedin, E., Holmes, E.C., DePasse, J.V., Pinilla, L.T., Fitch, A., Hamelin, M.E., Papenburg, J., Boivin, G., Presence of oseltamivir-resistant pandemic A/H1N1 minor variants before drug therapy with subsequent selection and transmission. J Infect Dis 206 (2012), 1504–1511.
20. GlaxoSmithKline, Zanamivir Investigator's Brochure. 2009.
21. Hayden, F.G., Antiviral resistance in influenza viruses—implications for management and pandemic response. N. Engl. J. Med. 354 (2006), 785–788.
22. Hayden, F.G., Cote, K.M., Douglas, R.G. Jr., Plaque inhibition assay for drug susceptibility testing of influenza viruses. Antimicrob. Agents Chemother. 17 (1980), 865–870.
23. Hurt, A.C., Holien, J.K., Parker, M., Kelso, A., Barr, I.G., Zanamivir-resistant influenza viruses with a novel neuraminidase mutation. J. Virol. 83 (2009), 10366–10373.
24. Ison, M.G., Gubareva, L.V., Atmar, R.L., Treanor, J., Hayden, F.G., Recovery of drug-resistant influenza virus from immunocompromised patients: a case series. J Infect Dis 193 (2006), 760–764.
25. Ison, M.G., Mishin, V.P., Braciale, T.J., Hayden, F.G., Gubareva, L.V., Comparative activities of oseltamivir and A-322278 in immunocompetent and immunocompromised murine models of influenza virus infection. J Infect Dis 193 (2006), 765–772.
26. Larder, B.A., Kemp, S.D., Harrigan, P.R., Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science 269 (1995), 696–699.
27. Li, T.C., Chan, M.C., Lee, N., Clinical implications of antiviral resistance in influenza. Virus 7 (2015), 4929–4944.
28. Markowitz, M., Nguyen, B.Y., Gotuzzo, E., Mendo, F., Ratanasuwan, W., Kovacs, C., Prada, G., Morales-Ramirez, J.O., Crumpacker, C.S., Isaacs, R.D., Gilde, L.R., Wan, H., Miller, M.D., Wenning, L.A., Teppler, H., Rapid and durable antiretroviral effect of the HIV-1 integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study. J. Acquir. Immune Defic. Syndr. 46 (2007), 125–133.
29. Markowitz, M., Nguyen, B.Y., Gotuzzo, E., Mendo, F., Ratanasuwan, W., Kovacs, C., Prada, G., Morales-Ramirez, J.O., Crumpacker, C.S., Isaacs, R.D., Campbell, H., Strohmaier, K.M., Wan, H., Danovich, R.M., Teppler, H., Sustained antiretroviral effect of raltegravir after 96 weeks of combination therapy in treatment-naive patients with HIV-1 infection. J. Acquir. Immune Defic. Syndr. 52 (2009), 350–356.
30. Marty, F.M., Man, C.Y., van der Horst, C., Francois, B., Garot, D., Manez, R., Thamlikitkul, V., Lorente, J.A., Alvarez-Lerma, F., Brealey, D., Zhao, H.H., Weller, S., Yates, P.J., Peppercorn, A.F., Safety and pharmacokinetics of intravenous zanamivir treatment in hospitalized adults with influenza: an open-label, multicenter, single-arm, phase II study. J Infect Dis 209 (2014), 542–550.
31. Matsuzaki, Y., Mizuta, K., Aoki, Y., Suto, A., Abiko, C., Sanjoh, K., Sugawara, K., Takashita, E., Itagaki, T., Katsushima, Y., Ujike, M., Obuchi, M., Odagiri, T., Tashiro, M., A two-year survey of the oseltamivir-resistant influenza A(H1N1) virus in Yamagata, Japan and the clinical effectiveness of oseltamivir and zanamivir. Virol. J., 7, 2010, 53.
32. McSharry, J.J., Weng, Q., Brown, A., Kulawy, R., Drusano, G.L., Prediction of the pharmacodynamically linked variable of oseltamivir carboxylate for influenza A virus using an in vitro hollow-fiber infection model system. Antimicrob. Agents Chemother. 53 (2009), 2375–2381.
33. Moscona, A., Oseltamivir resistance—disabling our influenza defenses. N. Engl. J. Med. 353 (2005), 2633–2636.
34. Petersen, E., Keld, D.B., Ellermann-Eriksen, S., Gubbels, S., Ilkjaer, S., Jensen-Fangel, S., Lindskov, C., Failure of combination oral oseltamivir and inhaled zanamivir antiviral treatment in ventilator- and ECMO-treated critically ill patients with pandemic influenza A (H1N1)v. Scand. J. Infect. Dis. 43 (2011), 495–503.
35. Pizzorno, A., Abed, Y., Rheaume, C., Boivin, G., Oseltamivir-zanamivir combination therapy is not superior to zanamivir monotherapy in mice infected with influenza A(H3N2) and A(H1N1)pdm09 viruses. Antivir. Res. 105 (2014), 54–58.
36. Richard, M., Ferraris, O., Erny, A., Barthelemy, M., Traversier, A., Sabatier, M., Hay, A., Lin, Y.P., Russell, R.J., Lina, B., Combinatorial effect of two framework mutations (E119V and I222L) in the neuraminidase active site of H3N2 influenza virus on resistance to oseltamivir. Antimicrob. Agents Chemother. 55 (2011), 2942–2952.
37. Sheu, T.G., Deyde, V.M., Okomo-Adhiambo, M., Garten, R.J., Xu, X., Bright, R.A., Butler, E.N., Wallis, T.R., Klimov, A.I., Gubareva, L.V., Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008. Antimicrob. Agents Chemother. 52 (2008), 3284–3292.
38. Takashita, E., Ejima, M., Itoh, R., Miura, M., Ohnishi, A., Nishimura, H., Odagiri, T., Tashiro, M., A community cluster of influenza A(H1N1)pdm09 virus exhibiting cross-resistance to oseltamivir and peramivir in Japan, November to December 2013. Euro Surveill., 19, 2014.
39. Watanabe, A., Yates, P.J., Murayama, M., Soutome, T., Furukawa, H., Evaluation of safety and efficacy of intravenous zanamivir in the treatment of hospitalized Japanese patients with influenza: an open-label, single-arm study. Antivir. Ther. 20 (2015), 415–423.
40. Zeuzem, S., Soriano, V., Asselah, T., Bronowicki, J.P., Lohse, A.W., Mullhaupt, B., Schuchmann, M., Bourliere, M., Buti, M., Roberts, S.K., Gane, E.J., Stern, J.O., Vinisko, R., Kukolj, G., Gallivan, J.P., Bocher, W.O., Mensa, F.J., Faldaprevir and deleobuvir for HCV genotype 1 infection. N. Engl. J. Med. 369 (2013), 630–639.